At present there are no approved predictive tumour- or serum-derived biomarkers guiding usage of anti-angiogenic therapies in patients with adenocarcinoma of NSCLC.The objective of this NIS is to examine whether genetic/genomic markers (alone or combined with clinical covariates) could be used to predict OS in NSCLC patients eligible for treatment with Vargatef®. The investigations in this study are exploratory in nature and considered to be hypothesis generating. The results from these investigations may help to expand our understanding of the disease and the response to Vargatef®.
Purpose:
Study Type
OBSERVATIONAL
Enrollment
260
Number of Participants With Overall Survival (OS) Event
Overall survival (OS) was defined as the time from start of entering the study to time of death. For the analysis of overall survival, participants were censored at the date of the last contact if the physician was no longer able to contact a participants or caregiver, and the vital status could not otherwise be determined. Enrolled participants who never received the combination therapy of docetaxel and Vargatef® were censored on the day of enrolment. Calculation of OS: For participants with known date of death: OS \[days\] = date of death - date of treatment start + 1 For participants known to be alive by the end of the study or at follow-up visit: OS (censored) \[days\] = date of last contact when the Patient was known to be alive - date of treatment start + 1.
Time frame: From start of entering the study until death or last contact date, up to 42 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
LK Krems
Krems, Austria
AKH - Medical University of Vienna
Vienna, Austria
Brussels - UNIV Saint-Luc
Brussels, Belgium
AZ Maria Middelares
Ghent, Belgium
AZ Sint-Lucas - Campus Sint Lucas
Ghent, Belgium
Ieper - HOSP Jan Yperman
Ieper, Belgium
Liège - HOSP CHR de la Citadelle
Liège, Belgium
Charleroi - UNIV CHU de Charleroi
Lodelinsart, Belgium
Roeselare - HOSP AZ Delta
Roeselare, Belgium
Herlev and Gentofte Hospital
Herlev, Denmark
...and 61 more locations